Archer Aviation and CRISPR Therapeutics Highlighted as Top Mid‑Cap Growth Picks

Analysts spotlight three mid‑cap growth stocks with strong long‑term upside: Archer Aviation, which is developing electric vertical‑takeoff‑and‑landing aircraft for commercial and defense use; CRISPR Therapeutics, whose gene‑editing treatment Casgevy targets rare blood disorders; and e.l.f. Beauty, a cosmetics firm noted for modest valuation. While Archer faces certification and profitability hurdles, CRISPR and e.l.f. are positioned for expansion in their respective markets.

Separately, Bank of America analysts identify eight stocks trading below $10 that may offer substantial upside. The list features Brazil’s major banks Itau Unibanco Holding and Banco Bradesco, along with utilities and industrial firms such as Companhia de Saneamento Basico do Estado de São Paulo, Blue Owl Capital, Grab Holdings, Full Truck Alliance, Gerdau and Ultrapar Participações. These companies are noted for solid fundamentals despite low share prices, and analysts assign target price increases ranging from 15% to 80%.